FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045058772> ?p ?o ?g. }

• W2045058772 endingPage "564" @default.
• W2045058772 startingPage "559" @default.
• W2045058772 abstract "Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. Several phase II studies have tested other single agents and different gemcitabine-based regimens in pancreatic cancer, but both response and survival rates have remained low. Irinotecan, a topoisomerase I inhibitor currently approved for the treatment of metastatic colon cancer, has also demonstrated improved response rate in patients with pancreatic cancer. Our purpose was to determine the activity and toxicity of this regimen in patients with unresectable or metastatic pancreatic cancer. Patients with histologically confirmed pancreatic adenocarcinoma received gemcitabine 1000 mg/m2 plus irinotecan 100 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle for 6-8 months. From February 2004 to April 2006, 33 patients were entered into this study, 32 of whom were evaluable for treatment response, toxicity, median time to progression, and median survival. Characteristics included a median age of 63 years (range 41-79), 21 males (64%), and 12 females (36%). One patient discontinued treatment due to adverse effects. The total number of cycles administered was 188 and the median number of cycles for patients was 5.6 (range 2-7). Thirty-two patients were assessable for toxicity and response. Grade 3 hematological toxicity occurred in 9% of patients and was primarily neutropenia. No grade >2 gastrointestinal toxicities or death due to treatment were observed. The most frequent nonhematological adverse event was fatigue. Ten patients responded to treatment with two complete responses (6.3%) and eight partial responses (25.0%), for an overall response rate of 31.3%; 11 patients achieved stable disease (34.3%). The median time to tumor progression and the median survival were 9.2 (95% CI: 6.0-12.4) and 11.8 (95% CI: 7.7-15.9) months, respectively, with a 2-year survival of 22%. On the basis of this trial, the combination of gemcitabine plus irinotecan, administered in a weekly schedule and at this dose, is well tolerated and offers encouraging activity in the treatment of advanced and/or metastatic pancreatic cancer." @default.
• W2045058772 created "2016-06-24" @default.
• W2045058772 creator A5000294183 @default.
• W2045058772 creator A5010889765 @default.
• W2045058772 creator A5015149840 @default.
• W2045058772 creator A5022764324 @default.
• W2045058772 creator A5038943478 @default.
• W2045058772 creator A5047475074 @default.
• W2045058772 creator A5053965155 @default.
• W2045058772 creator A5055228504 @default.
• W2045058772 creator A5057008368 @default.
• W2045058772 creator A5065725453 @default.
• W2045058772 creator A5068279218 @default.
• W2045058772 creator A5089145363 @default.
• W2045058772 date "2009-11-01" @default.
• W2045058772 modified "2023-09-25" @default.
• W2045058772 title "Gemcitabine Plus Irinotecan as First-Line Weekly Therapy in Locally Advanced and/or Metastatic Pancreatic Cancer" @default.
• W2045058772 doi "https://doi.org/10.3727/096504009789745610" @default.
• W2045058772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19806786" @default.
• W2045058772 hasPublicationYear "2009" @default.
• W2045058772 type Work @default.
• W2045058772 sameAs 2045058772 @default.
• W2045058772 citedByCount "10" @default.
• W2045058772 countsByYear W20450587722012 @default.
• W2045058772 countsByYear W20450587722013 @default.
• W2045058772 countsByYear W20450587722014 @default.
• W2045058772 countsByYear W20450587722015 @default.
• W2045058772 countsByYear W20450587722016 @default.
• W2045058772 countsByYear W20450587722019 @default.
• W2045058772 countsByYear W20450587722020 @default.
• W2045058772 crossrefType "journal-article" @default.
• W2045058772 hasAuthorship W2045058772A5000294183 @default.
• W2045058772 hasAuthorship W2045058772A5010889765 @default.
• W2045058772 hasAuthorship W2045058772A5015149840 @default.
• W2045058772 hasAuthorship W2045058772A5022764324 @default.
• W2045058772 hasAuthorship W2045058772A5038943478 @default.
• W2045058772 hasAuthorship W2045058772A5047475074 @default.
• W2045058772 hasAuthorship W2045058772A5053965155 @default.
• W2045058772 hasAuthorship W2045058772A5055228504 @default.
• W2045058772 hasAuthorship W2045058772A5057008368 @default.
• W2045058772 hasAuthorship W2045058772A5065725453 @default.
• W2045058772 hasAuthorship W2045058772A5068279218 @default.
• W2045058772 hasAuthorship W2045058772A5089145363 @default.
• W2045058772 hasBestOaLocation W20450587721 @default.
• W2045058772 hasConcept C121608353 @default.
• W2045058772 hasConcept C126322002 @default.
• W2045058772 hasConcept C141071460 @default.
• W2045058772 hasConcept C143998085 @default.
• W2045058772 hasConcept C197934379 @default.
• W2045058772 hasConcept C2776737053 @default.
• W2045058772 hasConcept C2777063308 @default.
• W2045058772 hasConcept C2778764654 @default.
• W2045058772 hasConcept C2780210213 @default.
• W2045058772 hasConcept C2780258809 @default.
• W2045058772 hasConcept C2780259306 @default.
• W2045058772 hasConcept C2781413609 @default.
• W2045058772 hasConcept C29730261 @default.
• W2045058772 hasConcept C526805850 @default.
• W2045058772 hasConcept C71924100 @default.
• W2045058772 hasConcept C90924648 @default.
• W2045058772 hasConceptScore W2045058772C121608353 @default.
• W2045058772 hasConceptScore W2045058772C126322002 @default.
• W2045058772 hasConceptScore W2045058772C141071460 @default.
• W2045058772 hasConceptScore W2045058772C143998085 @default.
• W2045058772 hasConceptScore W2045058772C197934379 @default.
• W2045058772 hasConceptScore W2045058772C2776737053 @default.
• W2045058772 hasConceptScore W2045058772C2777063308 @default.
• W2045058772 hasConceptScore W2045058772C2778764654 @default.
• W2045058772 hasConceptScore W2045058772C2780210213 @default.
• W2045058772 hasConceptScore W2045058772C2780258809 @default.
• W2045058772 hasConceptScore W2045058772C2780259306 @default.
• W2045058772 hasConceptScore W2045058772C2781413609 @default.
• W2045058772 hasConceptScore W2045058772C29730261 @default.
• W2045058772 hasConceptScore W2045058772C526805850 @default.
• W2045058772 hasConceptScore W2045058772C71924100 @default.
• W2045058772 hasConceptScore W2045058772C90924648 @default.
• W2045058772 hasIssue "11" @default.
• W2045058772 hasLocation W20450587721 @default.
• W2045058772 hasLocation W20450587722 @default.
• W2045058772 hasLocation W20450587723 @default.
• W2045058772 hasOpenAccess W2045058772 @default.
• W2045058772 hasPrimaryLocation W20450587721 @default.
• W2045058772 hasRelatedWork W1970564121 @default.
• W2045058772 hasRelatedWork W2031089613 @default.
• W2045058772 hasRelatedWork W2080060706 @default.
• W2045058772 hasRelatedWork W2083238673 @default.
• W2045058772 hasRelatedWork W2119638459 @default.
• W2045058772 hasRelatedWork W2167562354 @default.
• W2045058772 hasRelatedWork W2370468903 @default.
• W2045058772 hasRelatedWork W2900250713 @default.
• W2045058772 hasRelatedWork W2908011862 @default.
• W2045058772 hasRelatedWork W332524067 @default.
• W2045058772 hasVolume "17" @default.
• W2045058772 isParatext "false" @default.
• W2045058772 isRetracted "false" @default.
• W2045058772 magId "2045058772" @default.
• W2045058772 workType "article" @default.